Objective:
To explore practical strategies for selecting and administering sustained-release glaucoma therapies to improve adherence and intraocular pressure (IOP) control, which is crucial for preventing optic neuropathy.
Key Findings:
- Only 10% of patients persist with topical glaucoma drops for a year, highlighting significant adherence issues.
- Durysta and iDose TR have shown efficacy in IOP reduction with manageable side effects, making them viable alternatives.
- Implantable systems can enhance accessibility and adherence to treatment, addressing common barriers faced by patients.
Interpretation:
Implantable drug delivery systems represent a promising advancement in glaucoma management, potentially improving patient adherence and reducing the burden of daily medication, which is critical for long-term eye health.
Limitations:
- Concerns about corneal endothelial cell loss with repeated dosing of implants, as evidenced by clinical trials.
- Need for ongoing glaucoma management even after implant therapy, as the implants do not provide a permanent solution.
Conclusion:
Implantable drug delivery systems offer a viable alternative to traditional topical therapies, but patient education and management strategies remain crucial for ensuring long-term adherence and effective treatment.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.